OncLive | Ibrutinib Combo Achieves 100% Response Rate in Patients With NHL OncLive Adding ibrutinib to standard rituximab (R)-CHOP chemotherapy for non-Hodgkin lymphoma (NHL) resulted in an objective response rate of 100%, according to the results of a small preliminary clinical trial. The research was presented at the 2013 ASCO ... |
